Chemotherapy with Paclitaxel and Gemcitabine in Progressive Medullary and Thyroid Carcinoma of the Follicular Epithelium

被引:11
作者
Matuszczyk, A.
Petersenn, S.
Voigt, W.
Kegel, T.
Dralle, H.
Schmoll, H-J.
Bockisch, A.
Mann, K.
机构
[1] Univ Duisburg Essen, Dept Endocrinol, Essen, Germany
[2] Univ Duisburg Essen, Div Lab Res, Essen, Germany
[3] Univ Halle Wittenberg, Dept Internal Med, Halle, Germany
[4] Univ Halle Wittenberg, Dept Surg, Halle, Germany
[5] Univ Duisburg Essen, Dept Nucl Med, Essen, Germany
关键词
neoplasm; effect of therapy; malignant disease; endocrine tumor; PHASE-II EVALUATION; DOXORUBICIN PLUS CISPLATIN; CANCER CELL-LINES; TYROSINE KINASE; THERAPY; TRIAL; INHIBITION; ADRIAMYCIN; GROWTH;
D O I
10.1055/s-0029-1238294
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nine patients (mean age 53) with metastasizing, progressive, medullary (MTC), thyroid carcinoma and progressive, nonradioiodine accumulating thyroid carcinoma of the follicular epithelium (follicular carcinoma, FTC and papillary carcinoma, PTC) were treated with a combination of paclitaxel and gemcitabine between 2004 and 2006. Tumors were histologically classified as follicular in 5 patients (56%), as papillary in 2 patients (22%), and medullary in 2 patients (22%). Paclitaxel (90-100 mg/m(2)) and gemcitabine (1000 mg/m(2)) were applied for two, three, or 6 cycles every three weeks, depending on response and side effects. The effect of therapy was evaluated by radiographic imaging (CT images) and [(18)F]FDG-PET. All patients with papillary, follicular, or medullary thyroid carcinoma had continuous progression during restaging 14.8+/-8.8 weeks after initiation of chemotherapy, including one patient with stable disease after 3 cycles, but continuous progression after 6 cycles of chemotherapy. Paclitaxel and gemcitabine are not a valid chemotherapy option, in particular in patients with progressive, nonradioiodine-accumulating follicular thyroid carcinoma, who were already treated by other chemotherapeutic agents.
引用
收藏
页码:61 / 64
页数:4
相关论文
共 32 条
  • [1] Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo
    Ain, KB
    Tofiq, S
    Taylor, KD
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (10) : 3650 - 3653
  • [2] Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas
    Ain, Kenneth B.
    Lee, Charles
    Williams, Kevin D.
    [J]. THYROID, 2007, 17 (07) : 663 - 670
  • [3] [Anonymous], ONKOLOGE
  • [4] Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244
    Ball, Douglas W.
    Jin, Ning
    Rosen, D. Marc
    Dackiw, Alan
    Sidransky, David
    Xing, Mingzhao
    Nelkin, Barry D.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (12) : 4712 - 4718
  • [5] Diagnosis in medullary thyroid cancer with [18F]FDG-PET and improvement using a combined PET/CT scanner
    Bockisch, A
    Brandt-Mainz, K
    Görges, R
    Müller, S
    Stattaus, J
    Antoch, G
    [J]. ACTA MEDICA AUSTRIACA, 2003, 30 (01) : 22 - 25
  • [6] BONADONNA G, 1970, CANCER RES, V30, P2572
  • [7] The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer
    Brandt-Mainz, K
    Müller, SP
    Görges, R
    Saller, B
    Bockisch, A
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2000, 27 (05) : 490 - 496
  • [8] Sunitinib: From rational design to clinical efficacy
    Chow, Laura Q. M.
    Eckhardt, S. Gail
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (07) : 884 - 896
  • [9] COMBINED CHEMOTHERAPY WITH BLEOMYCIN, ADRIAMYCIN, AND PLATINUM IN ADVANCED THYROID-CANCER
    DEBESI, P
    BUSNARDO, B
    TOSO, S
    GIRELLI, ME
    NACAMULLI, D
    SIMIONI, N
    CASARA, D
    ZORAT, P
    FIORENTINO, MV
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1991, 14 (06) : 475 - 480
  • [10] EKMAN ET, 1990, OTOLARYNG CLIN N AM, V23, P523